Close Menu

NEW YORK — Arcis Biotechnology has signed an agreement to license its nucleic acid sample preparation and preservation technology to Spanish microRNA diagnostics developer Mirnax Biosens, the companies said today.

Under the terms of the deal, Mirnax will use Arcis' technology to improve the stability of miRNA biomarkers for early disease detection. The firms will also work together to develop a microfluidic device that integrates their respective technologies.

Additional terms were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
12
Sponsored by
Truvian

Antibody testing is expected to play an important role in the management of the COVID-19 pandemic. 

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.